Your browser doesn't support javascript.
loading
A retrospective analysis of the prevalence and impact of associated comorbidities on fibromyalgia outcomes in a tertiary care center.
Rivera, Fernando A; Munipalli, Bala; Allman, Madeleine E; Hodge, David O; Wieczorek, Mikolaj A; Wang, Benjamin; Abril, Andy; Perlman, Adam; Knight, Dacre; Bruce, Barbara.
Afiliación
  • Rivera FA; Division of General Internal Medicine, Mayo Clinic, Jacksonville, FL, United States.
  • Munipalli B; Division of General Internal Medicine, Mayo Clinic, Jacksonville, FL, United States.
  • Allman ME; Department of Psychology, University of Houston, Houston, TX, United States.
  • Hodge DO; Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, United States.
  • Wieczorek MA; Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, United States.
  • Wang B; Division of Rheumatology, Mayo Clinic, Jacksonville, FL, United States.
  • Abril A; Division of Rheumatology, Mayo Clinic, Jacksonville, FL, United States.
  • Perlman A; Division of General Internal Medicine, Mayo Clinic, Jacksonville, FL, United States.
  • Knight D; Division of General Internal Medicine, Mayo Clinic, Jacksonville, FL, United States.
  • Bruce B; Department of Psychiatry and Psychology, Mayo Clinic, Jacksonville, FL, United States.
Front Med (Lausanne) ; 10: 1301944, 2023.
Article en En | MEDLINE | ID: mdl-38288305
ABSTRACT

Background:

This retrospective study was designed to analyze the prevalence and impact of associated comorbidities on fibromyalgia (FM) outcomes (functionality, pain, depression levels) for patients who participated in an intensive multicomponent clinical program in a tertiary care center.

Methods:

Participants included a sample of 411 patients diagnosed with FM at a large tertiary medical center using the 2016 ACR criteria. Patients completed an intensive 2-day cognitive behavioral treatment (CBT) program, filled out the Fibromyalgia Impact Questionnaire Revised (FIQR), the Center for Epidemiologic Studies Depression Scale (CES-D), the Pain Catastrophizing Scale (PCS), and were followed for 6 months after treatment completion. T-tests were performed to analyze differences between the presence or absence of select comorbidities for the three outcomes at follow-up. Statistically significant comorbidities (p < 0.05) were used as predictors in multivariable logistic regression models.

Results:

The FM associated comorbidities in this cohort that had significant impact on the measured outcome domains after treatment program completed were Obesity (FIQR p = 0.024), Hypothyroidism (CES-D p = 0.023, PCS p = 0.035), Gastroesophageal reflux disease GERD (PCS p < 0.001), Osteoarthritis (CES-D p = 0.047). Interestingly, Headache, the most frequent FM associated comorbidity in this cohort (33.6%), did not have a significant impact on the outcome domains at follow-up. Obesity (18.2%) was the only FM associated comorbidity significantly impacting all three outcome domains at follow-up.

Conclusion:

The present study suggests that addressing obesity may significantly impact outcomes in FM patients.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Med (Lausanne) Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Med (Lausanne) Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos